221 related articles for article (PubMed ID: 7710929)
1. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.
Sark MW; Timmer-Bosscha H; Meijer C; Uges DR; Sluiter WJ; Peters WH; Mulder NH; de Vries EG
Br J Cancer; 1995 Apr; 71(4):684-90. PubMed ID: 7710929
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
3. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
Kikuchi Y; Hirata J; Yamamoto K; Ishii K; Kita T; Kudoh K; Tode T; Nagata I; Taniguchi K; Kuwano M
Jpn J Cancer Res; 1997 Feb; 88(2):213-7. PubMed ID: 9119751
[TBL] [Abstract][Full Text] [Related]
5. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
7. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
[TBL] [Abstract][Full Text] [Related]
9. Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
Matsumura T; Takigawa N; Kiura K; Shibayama T; Chikamori M; Tabata M; Ueoka H; Tanimoto M
In Vivo; 2005; 19(4):717-21. PubMed ID: 15999539
[TBL] [Abstract][Full Text] [Related]
10. Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression.
Murata T; Hatayama I; Kakizaki I; Satoh K; Sato K; Tsuchida S
Jpn J Cancer Res; 1996 Nov; 87(11):1171-8. PubMed ID: 9045947
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line.
Singh SV; Xu BH; Jani JP; Emerson EO; Backes MG; Rihn C; Scalamogna D; Stemmler N; Specht S; Blanock K
Int J Cancer; 1995 May; 61(3):431-6. PubMed ID: 7729958
[TBL] [Abstract][Full Text] [Related]
12. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
14. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
15. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
Shellard SA; Fichtinger-Schepman AM; Lazo JS; Hill BT
Anticancer Drugs; 1993 Aug; 4(4):491-500. PubMed ID: 8400352
[TBL] [Abstract][Full Text] [Related]
16. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.
Caliaro MJ; Vitaux P; Lafon C; Lochon I; Néhmé A; Valette A; Canal P; Bugat R; Jozan S
Br J Cancer; 1997; 75(3):333-40. PubMed ID: 9020476
[TBL] [Abstract][Full Text] [Related]
17. Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line.
Hong WS; Son YS
Anticancer Res; 1996; 16(5A):3031-6. PubMed ID: 8917423
[TBL] [Abstract][Full Text] [Related]
18. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line.
de Jong S; Timmer-Bosscha H; de Vries EG; Mulder NH
Int J Cancer; 1993 Jan; 53(1):110-7. PubMed ID: 8380054
[TBL] [Abstract][Full Text] [Related]
19. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
20. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
